Malaria Vaccines Market, By Agent Type (Plasmodium Falciparum, Plasmodium Vivax, and Anopheles Species), By Vaccine Type (Pre-Erythrocytic Vaccine, Erythrocytic Vaccine, and Multi-antigen Vaccine), By Distribution Channel (Hospitals, Clinics, and Community Centers), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2032

Report Code: PMI312119 | Publish Date: June 2023 | No. of Pages: 166

Global Malarial Vaccines Market By Overview

[PDF] The term malaria refers to a condition brought on by the plasmodium parasite, which is infected by mosquitoes and infects humans through their bites. Malaria vaccine refers to a biological component that promotes the formation of antibodies. Malaria causes symptoms such as fever, exhaustion, nausea, headaches, chills, etc. it can be given intramuscularly, subcutaneously, or intradermally. Pre-erythrocytic vaccinations, erythrocytic vaccines, and multi-antigen vaccines are the three broad categories of vaccines.

The increase in prevalence of malaria, particularly across tropical countries, is primarily driving the global malaria vaccine market. Many government and non-government organizations are starting encouraging campaigns to educate the public about disease prevention and the value of immunization, especially in endemic and rural areas. Thus, these factors have become the major contribution in the growth of the Malaria Vaccines Market. The introduction of pre-erythrocytic vaccines which is commonly known as anti-infective vaccines, targets the plasmodium parasite and prevents progression of chronic blood-stage diseases that has given rise to the demand for Malaria Vaccines Market.

Attributes

Details

Malaria Vaccines Market Value (2022)

US$ 2.4Bn

Malaria Vaccines Market Projected Value (2032)

US$ 52.8Bn

Malaria Vaccines Market CAGR (2022 – 2032)

34.1%

Global Malarial Vaccines Market By Dynamics

Rising prevalence of malaria in tropical regions

The increase in malaria prevalence in tropical regions has become the major factor to boost the market's growth rate. A potentially fatal infectious disease called malaria is conveyed by female Anopheles mosquitoes and is brought on by the Plasmodium parasite. Climate change is facilitating the expansion of the malaria epidemic and enhancing the viability of mosquito-borne diseases is also expected to drive the target market growth.

For instance, in 2019, according to WHO, there were around 229 million malaria infections and 409,000 fatalities, and has created a demand for malaria vaccines. Tropical regions including Africa, Asia, Central America, and South America have been most affected by malaria. Furthermore, Africa, Southeast Asia, the Eastern Mediterranean, and the Western Pacific are the regions where malaria is most prevalent.

Increasing investment in healthcare infrastructure

The rising investment in healthcare, which contributes to the development of its infrastructure, and are a crucial element for driving the market growth rate for malaria vaccines. The market dynamics would be further driven by various government organizations funding, efforts to strengthen the healthcare infrastructure by boosting the market growth. Factors like rising in geriatric population and rising focus on immunization development will also help in expanding the target market growth. Furthermore, increase in number of patient awareness level, government initiatives and the use of malaria vaccinations in more therapeutic situations will expand the malaria vaccines market.

For instance, in September 2022, India's drug regulator allowed the export of vaccine against malaria which was developed at the Jenner Institute by scientists at the University of Oxford and it was manufactured by Serum Institute to UK. The vaccine trial includes 409 children and they demonstrated that three initial doses followed by a booster dose is necessary for the protection against malaria disease.

Restrains:

High cost associated with drug development and distribution hinder the market's rate of expansion. The market for malaria vaccinations face difficulties due to a shortage of highly qualified workers and a lack of healthcare infrastructure in poor nations. Lack of awareness among people and technical challenge in vaccine development limit the Malaria Vaccines Market growth.

Access Crucial Insights at a Fraction of the Cost | Request Your Discount

Global Malarial Vaccines Market By Segmentation

Malaria Vaccines Market is segmented based on Agent Type, Vaccine Type, Distribution Channel and Region.

Agent Type Insight

On the basis of Agent Type, Malaria Vaccines Market is segmented into Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species. Plasmodium Vivax segment is expected to dominate the target market growth because of its unique biological and epidemiological characteristics in controlling of the diseases causing pathogen.

Vaccine type Insights

On the basis of vaccine type, Malaria Vaccines Market is segmented into Pre-Erythrocytic Vaccine, Erythrocytic Vaccine, and Multi-antigen Vaccine. Pre-Erythrocytic Vaccine is expected to dominate the target market growth because it targets the liver and sporozoite stages of Plasmodium and can also inhibit the development of blood-stage illness that cause millions of deaths per year.

Distribution channel Insights

On the basis of distribution channel, Malaria Vaccines Market is segmented Hospitals, Clinics, and Community Centres. Hospitals are expected to dominate target market due to availability of different various medical facilities under one roof, improved infrastructure, growing admission of patients and presence of skilled professionals.

Regional Insights:

Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.

On the basis of region, the Malaria Vaccines Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The Asia Pacific market is estimated to witness a significantly high revenue share over the forecast period due to rise in number of malaria patients and rising healthcare industry investment. The increasing target population base with high unmet clinical needs are anticipated to increase demand for malaria vaccines in the region.

Reduce costs by up to 30% with a custom report tailored to your specific needs | Request Customized Report

Report Scope:

Attribute

Details

Base year for estimation

2022

Forecast period

2022 – 2032

Market representation

Revenue in USD Billion & CAGR from 2022 to 2032

Market Segmentation

By Agent Type - Plasmodium Falciparum, Plasmodium Vivax, and Anopheles Species

By Vaccine Type - Pre-Erythrocytic Vaccine, Erythrocytic Vaccine, and Multi-antigen Vaccine

By Distribution channel – Hospitals, Clinics, and Community Centers

Regional scope

North America - U.S., Canada

Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe

Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific

Latin America - Brazil, Mexico, Argentina, Rest of Latin America

Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2022 to 2032. For the purpose of this study, has segmented the Malaria Vaccines Market report based on Agent Type, Vaccine Type, Distribution channel and Region:

Malaria Vaccines Market, By Agent Type:

  • Plasmodium Falciparum
  • Plasmodium Vivax
  • Anopheles Species

Malaria Vaccines Market, By Vaccine Type:

  • Pre-Erythrocytic Vaccine
  • Erythrocytic Vaccine
  • Multi-antigen Vaccine

Malaria Vaccines Market, By Distribution channel:

  • Hospitals
  • Clinics
  • Community Centers

Malaria Vaccines Market, By Region:

      • North America
          • U.S.
          • Canada
      • Europe
          • Germany
          • UK
          • France
          • Russia
          • Italy
          • Rest of Europe
      • Asia Pacific
          • China
          • India
          • Japan
          • South Korea
          • Rest of Asia Pacific
      • Latin America
          • Brazil
          • Mexico
          • Rest of Latin America
      • Middle East & Africa
          • GCC
          • Israel
          • South Africa
          • Rest of Middle East & Africa

Global Malarial Vaccines Market By Key Players

 

The key players operating the Malaria Vaccines Market GlaxoSmithKline LLC, Nobel Pharma Co., Ltd., GenVec, Inc., Sanaria, Inc., CellFree Sciences Co. Ltd., Cadila Healthcare Ltd., VLP Therapeutics LLC, Genome ReS Ltd. includes,

Global Malarial Vaccines Market By Company Profile

  • GlaxoSmithKline LLC*
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Nobel Pharma Co., Ltd.
  • GenVec, Inc.
  • Sanaria, Inc
  • CellFree Sciences Co. Ltd.
  • Cadila Healthcare Ltd.
  • VLP Therapeutics LLC
  • Genome ReS Ltd.

“*” marked represents similar segmentation in other categories in the respective section

Recent Development:

  • In 2023, World Health Organization (WHO) approved a new malaria vaccine known as Mosquirix from drugmaker GSK which was developed by researchers at Oxford University. It was accepted by both Ghana and Nigeria. It took 30 years to become first prequalification for a malaria vaccine and was an important step in rolling out the vaccine around the world.
  • In 2023, the country’s Food and Drugs Authority approved R21/Matrix-M which was developed by the Jenner Institute and manufactured by the Serum Institute of India leveraging Novavax’s adjuvant technology for the use in Ghana. The vaccine has been approved for use of children of age group between 5 to 36 months. 21/Matrix-M™ vaccine has been demonstrated a high level of efficacy and safety in Phase II trials. It is a three-dose regime.

Global Malarial Vaccines Market By Table of Contents

  1. Research Objective and Assumption
    • Preface
    • Research Objectives
    • Study Scope
    • Years Considered for the study
    • Assumptions
    • Abbreviations
  2. Research Methodology
    • Research data
    • Primary Data
      • Primary Interviews
      • Primary Breakdown
      • Key data from Primary Sources
      • Key Thickness Insights
    • Secondary Data
      • Major Secondary Sources
      • Secondary Sources
    • Market Estimation
    • Top-Down Approach
      • Approach for estimating Market Share by Top-Down Analysis (Supply Side)
    • Bottom-Up Approach
      • Approach for estimating market share by Bottom-up Analysis (Demand Side)
    • Market Breakdown and Data Triangulation
    • Research Assumptions
  3. Market Preview
    • Executive Summary
    • Key Findings—Global Outlook for medical carts Strategies
      • Key Questions this Study will Answer
      • Market Snippet, By Agent Type
      • Market Snippet, By Vaccine Type
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Opportunity Map Analysis
    • Executive Summary—3 Big Predictions
  4. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restrains
      • Market Opportunities
      • Market Trends
    • DR Impact Analysis
    • PEST Analysis
    • Porter’s Five Forces Analysis
    • Opportunity Orbit
    • Market Investment Feasibility Index
    • Macroeconomic Factor Analysis
  5. Malaria Vaccines Market, By Agent Type
    • Overview
      • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2022 – 2032
      • Y-o-Y Growth Analysis (%), 2022 – 2032
      • Segment Trends
    • Plasmodium Falciparum
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
    • Plasmodium Vivax
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
    • Anopheles Species
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
  6. Malaria Vaccines Market, By Vaccine Type, 2022 – 2032, (US$ Bn)
    • Overview                                      
      • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2022 – 2032
      • Y-o-Y Growth Analysis (%), 2022 – 2032
      • Segment Trends
    • Pre-Erythrocytic Vaccine
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
    • Erythrocytic Vaccine
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
    • Multi-antigen Vaccine
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
  7. Malaria Vaccines  Market, By Distribution Channel, 2022 – 2032, (US$ Bn)
    • Overview                                      
      • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2022 – 2032
      • Y-o-Y Growth Analysis (%), 2022 – 2032
      • Segment Trends
    • Hospitals
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
    • Clinics
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
    • Community Centers
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
  8. Malaria Vaccines Market, By Region, 2022 – 2032, (US$ Bn)
    • Overview
      • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2022 – 2032
      • Y-o-Y Growth Analysis (%), 2022 – 2032
      • Regional Trends
    • North America
      • Market Size and Forecast (US$ Bn), By Agent Type, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By Vaccine Type, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By Distribution Channel, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By Country, 2022 – 2032
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast (US$ Bn), By Agent Type, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By Vaccine Type, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By Distribution Channel, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By Country, 2022 – 2032
        • UK
        • France
        • Germany
        • Russia
        • Italy
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast (US$ Bn), By Agent Type, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By Vaccine Type, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By Distribution Channel, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By Country, 2022 – 2032
        • India
        • Japan
        • South Korea
        • China
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast (US$ Bn), By Agent Type, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By Vaccine Type, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By Distribution Channel, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By Country, 2022 – 2032
        • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East & Africa
      • Market Size and Forecast (US$ Bn), By Agent Type, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By Vaccine Type, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By Distribution Channel, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By Country, 2022 – 2032
        • GCC
        • Israel
        • South Africa
        • Rest of Middle East
  2. Competitive Landscape
    • Heat Map Analysis
    • Market Presence and Specificity Analysis
  3. Company Profiles
  • GlaxoSmithKline LLC.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Nobel Pharma Co., Ltd.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • GenVec, Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Sanaria, Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • CellFree Sciences Co. Ltd.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Cadila Healthcare Ltd.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • VLP Therapeutics LLC.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Genome ReS Ltd.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  1. The Last Word
    • Future Impact
    • About Us
    • Contact